We are live on ! Find out more
NGNE icon

Neurogene
NGNE

36 hedge funds and large institutions have $53.7M invested in Neurogene in 2019 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 7

36% more capital invested

Capital invested by funds: $39.3M → $53.7M (+$14.3M)

9% more funds holding

Funds holding: 33 → 36 (+3)

0% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 9

0.19% less ownership

Funds ownership: 3.54% → 3.35% (-0.19%)

Holders
36
Holders Change
+3
Holders Change %
+9.09%
% of All Funds
0.79%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
9
Reduced
9
Closed
7
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
-$3K

Top Buyers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
+$3.04M
2
Millennium Management
Millennium Management
New York
+$1.25M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$1.23M
4
BBA
Baker Bros. Advisors
New York
+$1.13M
5
Renaissance Technologies
Renaissance Technologies
New York
+$869K

Top Sellers

Rank Fund Capital Flow
1
OAM
Oxford Asset Management
United Kingdom
-$367K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$296K
3
EP
Eversept Partners
New York
-$174K
4
JP Morgan Chase
JP Morgan Chase
New York
-$114K
5
SIM
Spark Investment Management
New York
-$109K
Name Holding Trade Value Shares
Change 		Change in
Stake
KM
26
Kalos Management
Georgia
$42K – – –
State Street
27
State Street
Massachusetts
$35K – – –
Deutsche Bank
28
Deutsche Bank
Germany
$28K +$30.1K +494 New
TRCT
29
Tower Research Capital (TRC)
New York
$22K +$14.1K +231 +141%
Citigroup
30
Citigroup
New York
$14K – – –
UBS Group
31
UBS Group
Switzerland
$14K +$6.71K +110 +77%
TC
32
Truvestments Capital
Florida
$6K -$732 -12 -10%
Morgan Stanley
33
Morgan Stanley
New York
$5K +$3.54K +58 +141%
Bank of Montreal
34
Bank of Montreal
Ontario, Canada
$3K – – –
Simplex Trading
35
Simplex Trading
Illinois
$3K +$3.29K +54 New
EP
36
Eversept Partners
New York
– -$174K -3,686 Closed
JP Morgan Chase
37
JP Morgan Chase
New York
– -$114K -2,390 Closed
SIM
38
Spark Investment Management
New York
– -$109K -2,320 Closed
Charles Schwab
39
Charles Schwab
California
– -$40K -841 Closed
Squarepoint
40
Squarepoint
New York
– -$35K -748 Closed
PM
41
Prosight Management
Texas
– -$9K -182 Closed
CG
42
Cutler Group
California
– -$7K -150 Closed
Bank of America
43
Bank of America
North Carolina
– +$427 +7 New
1
2

NGNE Hedge Fund Activity: Q3 2019 in Review

36 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q3 2019, worth a combined $53.7M — up 36% from $39.3M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new NGNE positions and 7 closed out — a net gain of 3 holders — while 9 added to existing stakes and 9 trimmed.

The largest buyer was Opaleye Management, opening a new position worth an estimated $3.04M. The largest seller was Oxford Asset Management, cutting an estimated $367K.

  • 36 institutional investors held Neurogene (NGNE) as of Q3 2019, up from 33 in Q2 2019.
  • Funds reported $53.7M of Neurogene stock for Q3 2019, up 36% quarter-over-quarter.
  • 10 funds opened new Neurogene positions in Q3 2019 and 7 closed out, a net change of +3 holders.
  • The largest Neurogene buyer in Q3 2019 was Opaleye Management, an estimated $3.04M added.
  • The largest Neurogene seller in Q3 2019 was Oxford Asset Management, an estimated $367K sold.

Based on aggregated 13F filings for Q3 2019.